InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Rhea-AI Summary

InMed Pharmaceuticals (NASDAQ: INM) received a Nasdaq notice dated March 27, 2026 that the closing bid price was below the $1.00 minimum during the February 11, 2026–March 26, 2026 period.

The company has a 180-calendar day cure period to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days; trading will continue under the symbol INM.

Positive

• 180-day cure period to regain minimum bid price compliance
• Common shares will continue trading on Nasdaq during the compliance period
• Potential additional 180-day extension available if market value standards are met

Negative

• Closing bid price was below $1.00 for 30 consecutive trading days (Feb 11–Mar 26, 2026)
• Failure to regain compliance could lead to delisting from The Nasdaq Capital Market
• If delisting notice issues, shares may be automatically suspended pending any Nasdaq appeal

Key Figures

Nasdaq minimum bid: $1.00 per share Deficiency period: 30 consecutive trading days Initial cure window: 180 calendar days +5 more

8 metrics

Nasdaq minimum bid $1.00 per share Minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)

Deficiency period 30 consecutive trading days Period shares closed below $1.00 before notice (Feb 11–Mar 26, 2026)

Initial cure window 180 calendar days Time allowed to regain minimum bid compliance after Nasdaq notice

Compliance streak 10 consecutive business days Required period with bid at or above $1.00 to regain compliance

Additional grace 180 calendar days Potential second compliance period if initial efforts fail

Shelf registration size $50,000,000 Total amount of securities registered on S-3 shelf filed 2026-03-20

Non-affiliate value $2.6 million Aggregate market value of non-affiliate shares as of March 18, 2026

Non-affiliate shares 2,915,074 shares Non-affiliate common shares cited in S-3 filing

Market Reality Check

Price: $0.6558 Vol: Volume 145,647 is below 2...

low vol

$0.6558 Last Close

Volume Volume 145,647 is below 20-day average 231,071, suggesting muted pre-notice trading interest. low

Technical Shares at $0.6558 are trading below 200-day MA $1.78 and sit just above the 52-week low of $0.65.

Peers on Argus

Pre-notice action appears stock-specific. Scanner peers were mixed, with SBFM do...

1 Up 1 Down

Pre-notice action appears stock-specific. Scanner peers were mixed, with SBFM down about 2% and YCBD up about 2.78%, while other high-affinity peers showed both gains and losses.

Common Catalyst Same-day peer headlines focus on AI and technology initiatives rather than listing or compliance issues.

Historical Context

5 past events · Latest: Mar 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 23	Preclinical data update	Positive	-6.9%	INM-901 showed reduced neuroinflammation in 3D human brain organoid models.
Mar 09	Pipeline development	Positive	-3.7%	Outlined 2026 priorities advancing INM-901 and INM-089 toward INDs and trials.
Mar 06	Business refocus	Neutral	-3.7%	BayMedica wind-down and strategic shift to pharmaceutical pipeline with one-time costs.
Feb 11	Earnings and update	Mixed	-10.1%	Q2 FY2026 results with $7.0M cash, lower BayMedica revenue and ongoing losses.
Dec 17	Shareholder meeting	Positive	+7.5%	AGM approvals including directors, auditors and potential 20%+ share issuance under SEPA.

Pattern Detected

Recent news with positive or strategic tones has often been followed by negative price reactions, except for the December 2025 shareholder meeting results.

Recent Company History

Over the past six months, InMed has reported multiple pipeline and corporate updates, including preclinical advances in INM-901 and INM-089, winding down BayMedica’s operations, and Q2 FY2026 financials showing a $7.0M cash position and continued losses. Despite generally constructive R&D progress, shares typically declined after these announcements, with moves like -10.09% on the Q2 results and -6.92% on the March 23 neuroinflammation data. The current Nasdaq bid-price notice arrives against this backdrop of persistent price pressure.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2026-03-20

$50,000,000 registered capacity

An effective S-3 shelf filed on 2026-03-20 allows InMed to offer up to $50,000,000 of securities over time, providing capital-raising flexibility that could be used alongside other measures referenced in the Nasdaq compliance process.

Market Pulse Summary

This announcement confirms that InMed’s shares fell below Nasdaq’s $1.00 minimum bid for 30 consecut...

Analysis

This announcement confirms that InMed’s shares fell below Nasdaq’s $1.00 minimum bid for 30 consecutive trading days, triggering a formal 180-day compliance window. The company outlined standard options, including monitoring its price and potentially using a reverse stock split if needed. Recent filings also introduced a $50,000,000 shelf registration and reiterated going-concern language. Investors may watch for concrete compliance plans, capital-raising activity from the shelf, and progress on clinical milestones to contextualize listing risk.

Key Terms

nasdaq capital market, minimum bid price, reverse stock split, market value of publicly held shares, +2 more

6 terms

nasdaq capital market regulatory

"requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

minimum bid price regulatory

"closing bid price of the Company's common shares ... was below the minimum $1.00 per share requirement"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

reverse stock split financial

"intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

market value of publicly held shares financial

"required to meet the continued listing requirement for market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

delisting regulatory

"Nasdaq sill provide notice to the Company that its securities will be subject to delisting"

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

nasdaq hearings panel regulatory

"the Company may appeal such determination to a Nasdaq Hearings Panel (the "Panel")"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

AI-generated analysis. Not financial advice.

Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period.

The notice has no immediate impact on the listing of the Company's common shares, which will continue to trade on The Nasdaq Capital Market subject to the Company's continued compliance with the other listing requirements of The Nasdaq Capital Market.

In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance. To regain compliance, the closing bid price of the common shares of the Company must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. The common shares of the Company will continue to trade under the symbol "INM". The Company intends to monitor the closing share price for its common shares and explore available options to regain compliance.

In the event the Company does not evidence compliance with the minimum bid price requirement during the 180-day grace period, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, to Nasdaq. If it appears to the staff of Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Company will not be entitled to an additional 180 calendar days grace period and Nasdaq sill provide notice to the Company that its securities will be subject to delisting. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, it is expected that Nasdaq would notify the Company that its common shares are subject to delisting. If the Company is notified by Nasdaq that its securities are subject to delisting, the Company may appeal such determination to a Nasdaq Hearings Panel (the "Panel") but the Company's securities would be automatically suspended from trading on Nasdaq pending the completion of the appeal process. There can be no assurance that any such appeal would be successful or that the Company would be able to evidence compliance with the terms of any extension that may be granted by the Panel.

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small-molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: those relating to the Company's ability to regain compliance with the Nasdaq Capital Market minimum bid price requirement, including, without limitation, by effecting one or more stock splits if necessary; the impact of Nasdaq's notice on the listing of the Company's common shares on Nasdaq; and the Company's ability to meet the minimum stockholders' bid requirement for continued listing under Nasdaq listing rules or the success of any proposed appeal to the panel.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290289

FAQ

What did InMed (INM) say about the Nasdaq minimum bid price notice on March 27, 2026?

The company received a Nasdaq notice that its closing bid was below $1.00 for the Feb 11–Mar 26, 2026 period. According to the company, it has a 180-calendar day cure period to regain compliance by meeting the $1.00 close for 10 consecutive business days.

How long does InMed (INM) have to regain Nasdaq compliance after the March 27, 2026 notice?

InMed has a 180-calendar day period to cure the deficiency and meet the $1.00 closing bid requirement. According to the company, the period begins on the date of the written notice and requires 10 consecutive business days at or above $1.00.

What happens if InMed (INM) does not meet the $1.00 bid requirement within 180 days?

If InMed fails to regain compliance, it may be eligible for an extra 180-day extension if market value standards are met. According to the company, qualification requires meeting Nasdaq's market value and other initial listing standards except the bid price.

Will InMed (INM) shares remain listed and tradable after the March 27, 2026 Nasdaq notice?

Yes, the company's common shares will continue to trade on The Nasdaq Capital Market under INM during the compliance period. According to the company, there is no immediate impact on the listing while it seeks to regain compliance.

Could InMed (INM) be suspended or delisted if it fails to regain compliance?

Yes, failure to regain compliance could lead Nasdaq to notify the company that its securities are subject to delisting. According to the company, if notified, it may appeal but shares could be suspended pending the appeal process.

What options did InMed (INM) indicate it may pursue to regain Nasdaq compliance?

The company said it will monitor its share price and explore available options, including a possible reverse stock split if necessary. According to the company, a reverse split could be used to meet the minimum bid price requirement during a second compliance period.